This month’s “Virtual Lecture” discusses the health implications of the use of race in estimating glomerular filtration rate (eGFR), how to estimate GFR, and why it is important to continue funding and research to develop tools without the use of race.
A collaborative study between Mayo Clinic and the University of Illinois debunked the previous consensus about how kidney stones grow.
Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D. discusses the proper procedures for collecting and processing kidney stones in order to provide accurate, cost-effective analysis of patients’ kidney stones in a timely manner.
Mayo Clinic researchers are tracking the familiar characteristics of kidney stone formers in an online prediction tool that could help sufferers anticipate if they'll experience future episodes.
John Lieske, M.D., gives an overview of the phospholipase A2 receptor antibodies testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
This week’s Research Roundup highlights the evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
This week’s Research Roundup highlights predicting renal function outcomes after partial and radical nephrectomy.
This week’s Research Roundup highlights the clinical and pathology findings associated consistently with larger glomerular volume.
The National Kidney Foundation, the American Society for Clinical Pathology, and the nation’s leading laboratories and clinical laboratory societies have announced a new collaboration to remove barriers to testing for chronic kidney disease.
This week’s Research Roundup highlights how the DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN.
A team of Mayo Clinic pathologists have discovered a new tissue biomarker, DNAJB9, for fibrillary glomerulonephritis, a rare kidney disease of unknown pathogenesis and poor outlook—nearly half of all patients end up on dialysis within four years of diagnosis.